Wirth Manfred P, Froehner Michael
Department of Urology, University Hospital 'Carl Gustav Carus', Technical University of Dresden, Dresden, Germany.
Oncology. 2003;65 Suppl 1:1-4. doi: 10.1159/000072484.
Adjuvant hormonal therapy has been demonstrated to be able to delay disease progression in nonmetastatic prostate cancer. To date, however, a favorable impact on survival has only been demonstrated in lymph-node-positive disease and in external-beam radiotherapy series with locally advanced and probably mainly micrometastatic tumors. The Bicalutamide Early Prostate Cancer Program is the largest study under way to define the role of adjuvant treatment in early prostate cancer and identify subgroups of patients likely to benefit from immediate hormonal therapy. At the time of the most recently published analysis, the risk of objective clinical progression was significantly reduced in the bicalutamide arm (hazards ratio 0.58, 95% confidence interval 0.51-0.66, p < 0.0001). However, further maturation of data is needed to see whether this difference will lead to a survival advantage.
辅助激素治疗已被证明能够延缓非转移性前列腺癌的疾病进展。然而，迄今为止，仅在淋巴结阳性疾病以及局部晚期且可能主要为微转移肿瘤的外照射放疗系列中，证实了其对生存率有积极影响。比卡鲁胺早期前列腺癌研究项目是目前正在进行的最大规模研究，旨在确定辅助治疗在早期前列腺癌中的作用，并识别可能从即刻激素治疗中获益的患者亚组。在最近发表分析结果时，比卡鲁胺组客观临床进展风险显著降低（风险比0.58，95%置信区间0.51 - 0.66，p < 0.0001）。然而，需要数据进一步成熟，以观察这种差异是否会带来生存优势。
